predict and protect    

predict and protect

determine the risk of progression to advanced AMD

save the first eye    

save the first eye

92% of CNV patients treated by retina specialists maintain near normal vision with their second eye' Shouldn't they expect the same with their first?

genotype-directed therapy    

genotype-directed therapy

change the way you look at eye vitamins

the Macula Risk test    

the Macula Risk test

getting started is easy! sign up to become a provider.

Frontpage Slideshow | Copyright © 2006-2014 JoomlaWorks Ltd.

Macula Risk PGx
AMD Genetic Testing

Macula Risk® PGx is a combined prognostic and pharmacogenetic DNA test designed to determine a patient’s risk of progression to advanced Age-related Macular Degeneration (AMD) and aid in the selection of appropriate eye vitamin formulations for AMD based on his or her individual genetic risk profile.